Abstract
Author(s): Avan Khaleel Ismael*, Bushra Maree Jaralla
There are patients for whom autoimmune thyroid disease (AITD) presents obstacles during pregnancy—reducing adverse outcomes achieved by screening to detect abnormalities early. This research focuses on patients in the Kurdistan region and seeks to determine if regular screening for AITD during early pregnancy is effective. We tested 300 pregnant women for AITD during the first trimester; 150 were diseased, and 150 were controls. Thy function and autoantibody assays were tested from October 2022 to March 2024. Screening for autoimmune thyroid disease should be done regularly throughout early pregnancy for early intervention and risk reduction. The study found notable disparities in thyroid function, autoantibody levels, and inflammatory markers between the patient and control groups, indicating a greater occurrence of thyroid malfunction and inflammation in individuals with autoimmune thyroid illness. The differentiation was emphasized by key markers such as TSH, FT4, FT3, IL-6, and vitamin D levels, underlining the significance of early prenatal screening in high-risk patients. Maternal and newborn outcomes may be improved by using these screening measures.